These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 33987350)

  • 21. Safety and Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma.
    Yang F; Yang J; Xiang W; Zhong BY; Li WC; Shen J; Zhang S; Yin Y; Sun HP; Wang WS; Zhu XL
    Front Oncol; 2021; 11():657512. PubMed ID: 35096555
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Efficacy and safety of anti-PD-1 monoclonal antibody in advanced hepatocellular carcinoma after TACE combined with TKI therapy].
    Xu ZN; Huang JJ; Zhou J; Huang WS; Guo YJ; Cai MY; Zhou JW; Lin LT; Liang LC; Zhu KS
    Zhonghua Nei Ke Za Zhi; 2021 Jul; 60(7):630-636. PubMed ID: 34619840
    [No Abstract]   [Full Text] [Related]  

  • 23. Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study.
    Jin ZC; Chen JJ; Zhu XL; Duan XH; Xin YJ; Zhong BY; Chen JZ; Tie J; Zhu KS; Zhang L; Huang M; Piao MJ; Li X; Shi HB; Liu RB; Xu AB; Ji F; Wu JB; Shao GL; Li HL; Huang MS; Peng ZY; Ji JS; Yuan CW; Liu XF; Hu ZC; Yang WZ; Yin GW; Huang JH; Ge NJ; Qi X; Zhao Y; Zhou JW; Xu GH; Tu Q; Lin HL; Zhang YJ; Jiang H; Shao HB; Su YJ; Chen TS; Shi BQ; Zhou X; Zhao HT; Zhu HD; Ren ZG; Teng GJ;
    EClinicalMedicine; 2024 Jun; 72():102622. PubMed ID: 38745965
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibodies with Hepatic Arterial Infusion Chemotherapy or Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma.
    Yu B; Zhang N; Feng Y; Zhang Y; Zhang T; Wang L
    J Hepatocell Carcinoma; 2023; 10():1735-1748. PubMed ID: 37822726
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of anti-PD-1/PD-L1 antibodies combined with VEGF receptor tyrosine kinase inhibitors versus bevacizumab in unresectable hepatocellular carcinoma.
    Zeng H; Xu Q; Wang J; Xu X; Luo J; Zhang L; Luo C; Ying J; Li J
    Front Immunol; 2023; 14():1073133. PubMed ID: 36756114
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Significance of Transarterial Chemo(Embolization) Combined With Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review.
    Ke Q; Xin F; Fang H; Zeng Y; Wang L; Liu J
    Front Immunol; 2022; 13():913464. PubMed ID: 35677059
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Utility and predictive value of the CRAFITY score in advanced hepatocellular carcinoma treated with transarterial chemoembolization plus tyrosine kinase inhibitors and PD-1 inhibitor.
    Zhang L; Sun T; Sun B; Zhang K; Zheng Y; Li N; Chen L; Zheng C; Liang B; Shi H
    BMC Cancer; 2024 Feb; 24(1):223. PubMed ID: 38365678
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: A tertiary medical center experience.
    Luo L; Xiao Y; Zhu G; Huang A; Song S; Wang T; Ge X; Xie J; Deng W; Hu Z; Wen W; Mei H; Wan R; Shan R
    Front Oncol; 2022; 12():1004652. PubMed ID: 36237309
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and Safety of Transarterial Chemoembolization Plus Donafenib with or without Immune Checkpoint Inhibitors as the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis.
    Deng L; Sun Y; Wang H; Liao C; Li D; Xu G; Yang X
    J Hepatocell Carcinoma; 2024; 11():29-38. PubMed ID: 38223554
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and Safety of Lenvatinib Combined With PD-1 Inhibitors Plus TACE for Unresectable Hepatocellular Carcinoma Patients in China Real-World.
    Li X; Fu Z; Chen X; Cao K; Zhong J; Liu L; Ding N; Zhang X; Zhai J; Qu Z
    Front Oncol; 2022; 12():950266. PubMed ID: 35860582
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of regorafenib in combination with immune checkpoint inhibitor therapy as second-line and third-line regimen for patients with advanced hepatocellular carcinoma: a retrospective study.
    Zhao J; Guo Y; Feng T; Rong D; Kong X; Huang T; Lopez-Lopez V; Yarmohammadi H; Sakamoto Y; Zhu D; Yao A; Xia Y
    J Gastrointest Oncol; 2023 Dec; 14(6):2549-2558. PubMed ID: 38196523
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic efficacy and prognostic factors of TACE plus TKI with ICIs for the treatment of unresectable hepatocellular carcinoma: A retrospective study.
    Han Z; Yang F; Zhang Y; Wang J; Ni Q; Zhu H; Zhou X; Gao H; Lu J
    Front Oncol; 2022; 12():1029951. PubMed ID: 36591442
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
    Ren Z; Xu J; Bai Y; Xu A; Cang S; Du C; Li Q; Lu Y; Chen Y; Guo Y; Chen Z; Liu B; Jia W; Wu J; Wang J; Shao G; Zhang B; Shan Y; Meng Z; Wu J; Gu S; Yang W; Liu C; Shi X; Gao Z; Yin T; Cui J; Huang M; Xing B; Mao Y; Teng G; Qin Y; Wang J; Xia F; Yin G; Yang Y; Chen M; Wang Y; Zhou H; Fan J;
    Lancet Oncol; 2021 Jul; 22(7):977-990. PubMed ID: 34143971
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study.
    Ding X; Sun W; Li W; Shen Y; Guo X; Teng Y; Liu X; Zheng L; Li W; Chen J
    Cancer; 2021 Oct; 127(20):3782-3793. PubMed ID: 34237154
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transarterial Chemoembolization Combined with Atezolizumab Plus Bevacizumab or Lenvatinib for Unresectable Hepatocellular Carcinoma: A Propensity Score Matched Study.
    Zhao C; Xiang Z; Li M; Wang H; Liu H; Yan H; Huang M
    J Hepatocell Carcinoma; 2023; 10():1195-1206. PubMed ID: 37521029
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined transarterial chemoembolization and tislelizumab for patients with unresectable hepatocellular carcinoma.
    Tan BB; Fu Y; Shao MH; Chen HL; Liu P; Fan C; Zhang H
    World J Gastrointest Surg; 2024 Sep; 16(9):2829-2841. PubMed ID: 39351562
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of transcatheter arterial chemoembolization-lenvatinib sequential therapy for patients with unresectable hepatocellular carcinoma: a single-arm clinical study.
    Chen R; Li L; Li Y; Song K; Shen C; Ma P; Wang Z
    J Gastrointest Oncol; 2022 Jun; 13(3):1367-1375. PubMed ID: 35837188
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The safety and efficacy of TACE combined with HAIC, PD-1 inhibitors, and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a retrospective study.
    Huang Z; Wu Z; Zhang L; Yan L; Jiang H; Ai J
    Front Oncol; 2024; 14():1298122. PubMed ID: 38318115
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and Safety Analysis of Transarterial Chemoembolization Plus Donafenib With or Without Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma: A Prospective, Single-Arm, Single-Center, Phase II Clinical Study.
    Li J; Li Y; Song J; Zhao L
    J Hepatocell Carcinoma; 2024; 11():1207-1219. PubMed ID: 38946843
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study.
    Fu Z; Li X; Zhong J; Chen X; Cao K; Ding N; Liu L; Zhang X; Zhai J; Qu Z
    Hepatol Int; 2021 Jun; 15(3):663-675. PubMed ID: 33877527
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.